Arrowhead Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This Sustainability rating for Arrowhead Pharmaceuticals Inc represents its transparency towards the United Nations Sustainable Development Goals. Other companies in the rating peer group for Arrowhead Pharmaceuticals Inc are shown below. Full ESG analysis of Arrowhead Pharmaceuticals Inc can be accessed by logging in.
Arrowhead Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 2.3, social score of 5.0 and governance score of 6.0.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1156 | Vectus Biosystems Ltd | 4.7 | High |
| 1156 | Zynerba Pharmaceuticals Inc | 4.7 | High |
| 1199 | Arrowhead Pharmaceuticals Inc | 4.6 | High |
| 1199 | Allergan Inc | 4.6 | High |
| 1199 | AroCell AB (publ) | 4.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Arrowhead Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Arrowhead Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Arrowhead Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Arrowhead Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Arrowhead Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Arrowhead Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Arrowhead Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.